Natus to axe more jobs in restructuring initiative
This article was originally published in Clinica
As part of a new integration and restructuring programme, Natus Medical is set to lay off more staff from a number of its North American facilities. The San Carlos, California-based company, which develops products for newborn screening and care, as well as sleep and neurology diagnostics, said it is aiming to cut costs from its recently-acquired Excel-Tech subsidiary and improve the efficiency of its operations. The total number of redundancies was not disclosed.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.